Moderna’s Cancer Vaccine Gives Stock a New Growth Story. Will It Have a Happy Ending?

Moderna and Merck’s personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.